Nuedexta is a medicinal drug owned by Avanir Pharms. The active ingredients of Nuedexta are Dextromethorphan Hydrobromide and Quinidine Sulfate. It was first authorised for market use on 29 October, 2010. Nuedexta holds a total of 2 drug patents, out of which one has already expired.
The generic version of Nuedexta is expected to be released after 13 August, 2026. This generic release date is reliant on the expiry of the drug's last patent which is due on the same date.
Nuedexta, with its active ingredients Dextromethorphan Hydrobromide and Quinidine Sulfate, can be used effectively for the treatment of pseudobulbar affect. It is available in the form of an oral capsule.
Nuedexta has 2 drug patents. The patent 'US8227484' has already expired. The remaining patent 'US7659282' titled 'Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders' is due to expire on 13 August, 2026, upon which the Nuedexta generic is expected to be released. Below are the details of the patent: